echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Parkinson's drug CVN424, good news from clinical trials!

    Parkinson's drug CVN424, good news from clinical trials!

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Parkinson's disease is a chronic neurodegenerative disease affecting the central nervous system, primarily the motor nervous system
    .
    Its symptoms usually appear slowly over time, with tremors, limb stiffness, decreased motor function, and abnormal gait being the most obvious early symptoms, and cognitive and behavioral problems may also be present; dementia is fairly common in severely ill patients, with more than three Major depressive disorder and anxiety disorders also occur in about one in two cases


    .


    Recently, the pharmaceutical company Cerevance announced the latest results of the Phase II trial of the oral drug CVN424 in the treatment of Parkinson's disease
    .
    Cerevance focuses on the treatment of disorders of the brain and central nervous system (CNS)


    .


    Figure 1.
    Molecular formula of CVN424

    The drug was tested in a Phase II, randomized, double-blind, placebo-controlled, multicenter study involving approximately 135 Parkinson's disease patients
    .
    Patients received low-dose, high-dose CVN424 or a placebo in addition to standard Parkinson's disease medications such as levodopa


    .


    In addition to meeting safety endpoints, CVN424 was able to significantly reduce the time to recurrence of Parkinson's symptoms, known as "off time


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.